Literature DB >> 23718072

[Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study].

V I Zemel'ko, I B Kozhukharova, L L Alekseenko, A P Domnina, G F Reshetnikova, M V Puzanov, R I Dmitrieva, T M Grinchuk, N N Nikol'skiĭ, S V Anisimov.   

Abstract

Mesenchymal stem cells (MSCs) can be isolated from many adult tissue sources. These cells are a valuable substrate in cell therapy for many diseases and injuries. Different types of MSCs vary in plasticity. We performed a comparative study of the neurogenic potential of three types of human MSCs derived from bone marrow (BMSCs), subcutaneous adipose tissue (ADSCs) and endometrium (isolated from the menstrual blood) (eMSCs). It was shown that all three types of MSC cultures demonstrate multipotent plasticity and predisposition to neurogenesis, based on the expression of pluripotency markers SSEA-4 and neuronal precursors' markers nestin and beta-III-tubulin. Further analysis revealed the transcription of the neuronal marker MAP2 and neurotrophin-3 in undifferentiated BMSCs and ADSCs. Additionally, a significant basal level of synthesis of brain-derived neurotrophic factor (BDNF) in eMSC culture was also observed. Stimulation of neural induction with such agents as 5-azacytidine, recombinant human basic fibroblast growth factor (bFGF), recombinant human epidermal growth factor (EGF), a recombinant human fibroblast growth factor 8 (FGF8), morphogen SHH (sonic hedgehog), retinoic acid (RA) and isobutyl-methyl-xanthine (IBMX), showed further differences in the neurogenic potential of the MSCs. The components of the extracellular matrix, such as Matrigel and laminin, were also the important inducers of differentiation. The most effective neural induction in BMSCs proceeded without the RA participation while the cells pretreated with 5-azacytidine. In contrary, in the case of eMSCs RA was a necessary agent of neural differentiation as it stimulated the transcription of neurotrophin-4 and the elevation of secretion level of BDNF. The use of laminin as the substrate in eMSCs appeared to be critical, though an incubation of the cells with 5-azacytidine was optional. As far as ADSCs, RA in combination with 5-azacytidine caused the elevation of expression of MAP2, but reduced the secretion of BDNF. Thus, the effect of RA on neural differentiation of ADSCs in ambiguous and, together with the study of its signaling pathways in the MSCs, requires further research. The therapeutic effect of transplanted MSCs is commonly explained by their paracrine activity. The high basal level of BDNF synthesis in the eMSCs, along with their high proliferative rate, non-invasive extraction and neural predisposition, is a powerful argument for the use of the intact eMSCs as a substrate in cell therapy to repair nerve tissue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23718072

Source DB:  PubMed          Journal:  Tsitologiia        ISSN: 0041-3771


  15 in total

1.  Histological experimental study on the effect of stem cell therapy on adriamycin induced chemobrain.

Authors:  Maha Baligh Zickri; Dalia Hussein Abd El Aziz; Hala Gabr Metwally
Journal:  Int J Stem Cells       Date:  2013-11       Impact factor: 2.500

2.  Therapeutic doses of doxorubicin induce premature senescence of human mesenchymal stem cells derived from menstrual blood, bone marrow and adipose tissue.

Authors:  Irina Kozhukharova; Victoria Zemelko; Zoya Kovaleva; Larisa Alekseenko; Olga Lyublinskaya; Nikolay Nikolsky
Journal:  Int J Hematol       Date:  2017-10-11       Impact factor: 2.490

3.  Reactive Oxygen Species Are Required for Human Mesenchymal Stem Cells to Initiate Proliferation after the Quiescence Exit.

Authors:  O G Lyublinskaya; Ya G Borisov; N A Pugovkina; I S Smirnova; Ju V Obidina; Ju S Ivanova; V V Zenin; A N Shatrova; A V Borodkina; N D Aksenov; V I Zemelko; E B Burova; M V Puzanov; N N Nikolsky
Journal:  Oxid Med Cell Longev       Date:  2015-07-27       Impact factor: 6.543

4.  Injured Nerve Regeneration using Cell-Based Therapies: Current Challenges.

Authors:  E S Petrova
Journal:  Acta Naturae       Date:  2015 Jul-Sep       Impact factor: 1.845

5.  Murine embryos exposed to human endometrial MSCs-derived extracellular vesicles exhibit higher VEGF/PDGF AA release, increased blastomere count and hatching rates.

Authors:  Rebeca Blázquez; Francisco Miguel Sánchez-Margallo; Verónica Álvarez; Elvira Matilla; Nuria Hernández; Federica Marinaro; María Gómez-Serrano; Inmaculada Jorge; Javier G Casado; Beatriz Macías-García
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

6.  Human menstrual blood-derived stem cells promote functional recovery in a rat spinal cord hemisection model.

Authors:  Qinfeng Wu; Qinghua Wang; Zhangjie Li; Xiangzhe Li; Jing Zang; Zhangwei Wang; Chen Xu; Yujia Gong; Jiaqi Cheng; Haoming Li; Guangyu Shen; Chuanming Dong
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

Review 7.  Perspectives on the use of stem cells for autism treatment.

Authors:  Dario Siniscalco; James Jeffrey Bradstreet; Nataliia Sych; Nicola Antonucci
Journal:  Stem Cells Int       Date:  2013-10-10       Impact factor: 5.443

8.  Comparative Study of Microtubule-associated Protein-2 and Glial Fibrillary Acidic Proteins during Neural Induction of Human Bone Marrow Mesenchymal Stem Cells and Adipose-Derived Stem Cells.

Authors:  Fatemeh Sadat Mostafavi; Shahnaz Razavi; Mohammad Mardani; Ebrahim Esfandiari; Hamid Zarkesh Esfahani; Mohammad Kazemi
Journal:  Int J Prev Med       Date:  2014-05

9.  Changes of neural markers expression during late neurogenic differentiation of human adipose-derived stem cells.

Authors:  Shahnaz Razavi; Zahra Khosravizadeh; Hamid Bahramian; Mohammad Kazemi
Journal:  Adv Biomed Res       Date:  2015-09-28

10.  N-Cadherin Upregulation Promotes the Neurogenic Differentiation of Menstrual Blood-Derived Endometrial Stem Cells.

Authors:  Yanli Liu; Fen Yang; Shengying Liang; Qing Liu; Sulei Fu; Zhenyu Wang; Ciqing Yang; Juntang Lin
Journal:  Stem Cells Int       Date:  2018-03-05       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.